Treatment with mavacoxib reduced proliferation, cancer cell viability, and cancer stem cell viability while inducing caspase-independent apoptosis in canine cancer cell lines in a dose-dependent manner independently of COX-2 expression levels [111]. This evidence concerns the gene PTGER2 and cancer.